13th Annual Biotech and Specialty Pharmaceuticals Conference

The biotech sector has rebounded off its Q1 lows of the year, but does the industry have what it takes to survive the long term? The major biotech indexes are either matching or outperforming the S&P 500. At the beginning of October, the Nasdaq Biotech Stock Index (NBI) was up nearly 10% YTD and the AMEX Biotech Index (BTK) had gains of almost 40%. The S&P 500 was up approximately 10%.

Despite the ripple effects of the credit crisis and the uncertainty of the global economy, many analysts expect the biotech sector to outperform by the end of 2009 and throughout 2010.  Increasing M&A activity is expected into next year, serving as the biggest driver behind sector gains. Larger companies seeking bigger pipelines will continue to look for deals as smaller biotech companies face a cash crunch. 

However, experts say that while the fundamentals behind biotech and specialty pharmaceuticals’ growth —an aging population and the ever-growing demand for healthcare—remain, investors are now looking at companies’ cash positions more than ever before. This is particularly true in the case of small- and micro-caps, where cash on hand and ability to access capital are most critical to survival.

Don’t miss this chance to learn about opportunities in investing in specialty pharmaceutical and biotechnology companies. The CEOs, CFOs, and other executives from some of the industry’s most innovative small- and micro-cap companies will discuss their plans to invent, develop, research, and market important new drugs, diagnostics, and delivery technologies.

Sponsor	Media Partner	PDF

If you would like to media partner or sponsor any of these programs, please contact sponsorship@nyssa.org.

Agenda